DK154289C - ANALOGY PROCEDURE FOR THE PREPARATION OF N2-ARYLSULPHONYL-L-ARGININAMIDES OR SALTS THEREOF - Google Patents

ANALOGY PROCEDURE FOR THE PREPARATION OF N2-ARYLSULPHONYL-L-ARGININAMIDES OR SALTS THEREOF

Info

Publication number
DK154289C
DK154289C DK550576A DK550576A DK154289C DK 154289 C DK154289 C DK 154289C DK 550576 A DK550576 A DK 550576A DK 550576 A DK550576 A DK 550576A DK 154289 C DK154289 C DK 154289C
Authority
DK
Denmark
Prior art keywords
argininamides
arylsulphonyl
salts
preparation
analogy procedure
Prior art date
Application number
DK550576A
Other languages
Danish (da)
Other versions
DK154289B (en
DK550576A (en
Inventor
Shosuke Okamoto
Ryoji Kikumoto
Yoshikuni Tamao
Kazuo Ohkubo
Tohru Tezuka
Shinji Tonomura
Akiko Hijikata
Original Assignee
Mitsubishi Chem Ind
Shosuke Okamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/638,985 external-priority patent/US4055636A/en
Priority claimed from US05/646,522 external-priority patent/US4018915A/en
Priority claimed from US05/649,219 external-priority patent/US4018913A/en
Priority claimed from US05/653,217 external-priority patent/US4055651A/en
Priority claimed from US05/656,014 external-priority patent/US4041156A/en
Priority claimed from US05/656,870 external-priority patent/US4046876A/en
Priority claimed from JP3062176A external-priority patent/JPS52113919A/en
Priority claimed from US05/669,743 external-priority patent/US4070457A/en
Priority claimed from US05/707,536 external-priority patent/US4036955A/en
Priority claimed from US05/713,486 external-priority patent/US4073914A/en
Priority claimed from US05/723,474 external-priority patent/US4096255A/en
Priority claimed from US05/728,051 external-priority patent/US4104392A/en
Application filed by Mitsubishi Chem Ind, Shosuke Okamoto filed Critical Mitsubishi Chem Ind
Publication of DK550576A publication Critical patent/DK550576A/en
Publication of DK154289B publication Critical patent/DK154289B/en
Publication of DK154289C publication Critical patent/DK154289C/en
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/22—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK550576A 1975-12-09 1976-12-08 ANALOGY PROCEDURE FOR THE PREPARATION OF N2-ARYLSULPHONYL-L-ARGININAMIDES OR SALTS THEREOF DK154289C (en)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US05/638,985 US4055636A (en) 1974-11-08 1975-12-09 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US63898575 1975-12-09
US05/646,522 US4018915A (en) 1976-01-05 1976-01-05 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US64652276 1976-01-05
US64921976 1976-01-14
US05/649,219 US4018913A (en) 1976-01-14 1976-01-14 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/653,217 US4055651A (en) 1974-11-08 1976-01-28 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US65321776 1976-01-28
US65601476 1976-02-06
US05/656,014 US4041156A (en) 1974-11-08 1976-02-06 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/656,870 US4046876A (en) 1974-11-08 1976-02-10 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US65687076 1976-02-10
JP3062176 1976-03-19
JP3062176A JPS52113919A (en) 1976-03-19 1976-03-19 Preparation of tertiary alkylester of n-substituted amino acid or thei r acid salts
US05/669,743 US4070457A (en) 1974-11-08 1976-03-24 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US66974376 1976-03-24
US05/707,536 US4036955A (en) 1976-07-22 1976-07-22 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US70753676 1976-07-22
US71348676 1976-08-11
US05/713,486 US4073914A (en) 1974-11-08 1976-08-11 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US72347476 1976-09-14
US05/723,474 US4096255A (en) 1974-11-08 1976-09-14 N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US05/728,051 US4104392A (en) 1974-11-08 1976-09-30 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US72805176 1976-09-30

Publications (3)

Publication Number Publication Date
DK550576A DK550576A (en) 1977-06-10
DK154289B DK154289B (en) 1988-10-31
DK154289C true DK154289C (en) 1989-03-28

Family

ID=27583260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK550576A DK154289C (en) 1975-12-09 1976-12-08 ANALOGY PROCEDURE FOR THE PREPARATION OF N2-ARYLSULPHONYL-L-ARGININAMIDES OR SALTS THEREOF

Country Status (12)

Country Link
BE (1) BE849196A (en)
CA (1) CA1102316A (en)
DD (1) DD128681A5 (en)
DE (1) DE2655636A1 (en)
DK (1) DK154289C (en)
FI (1) FI65240C (en)
FR (1) FR2334349A1 (en)
GR (1) GR63103B (en)
LU (1) LU76347A1 (en)
NL (1) NL177747C (en)
NO (1) NO145379C (en)
PT (1) PT65934B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203887D0 (en) * 1982-06-23 1982-06-23 Kabivitrum Ab NEW TROMBIN INHIBITIVE ASSOCIATIONS
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
ZA986827B (en) * 1997-07-31 2000-05-02 Athena Neurosciences Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
ATE455106T1 (en) 1999-01-22 2010-01-15 Elan Pharm Inc ACYL DERIVATIVES FOR THE TREATMENT OF VLA-4 RELATED DISEASES
AU3348700A (en) * 1999-01-25 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CA2851103A1 (en) 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
DK1940826T3 (en) 2005-09-29 2011-04-18 Elan Pharm Inc Pyrimidinylamide compounds that inhibit leukocyte adhesion mediated through BLA-4
WO2007101165A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2760151A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL165652C (en) * 1973-08-13 1981-05-15 Mitsubishi Chem Ind METHOD FOR PREPARING AN ANTI-THROMBOSIS ACTION PREPARATION AND / OR BLOOD THROMBINE DIAGNOSTIC BASED ON L-ARGININE DERIVATIVES, THE PREPARED PREPARATION, THE PREPARED DIAGNOSTIC AND METHOD OF PREPARATION.

Also Published As

Publication number Publication date
NO145379C (en) 1982-03-10
CA1102316A (en) 1981-06-02
FI65240C (en) 1984-04-10
NO145379B (en) 1981-11-30
PT65934B (en) 1978-06-13
FI763528A (en) 1977-06-10
NL177747C (en) 1985-11-18
DK154289B (en) 1988-10-31
FI65240B (en) 1983-12-30
DD128681A5 (en) 1977-12-07
NO764186L (en) 1977-06-10
DK550576A (en) 1977-06-10
BE849196A (en) 1977-06-08
LU76347A1 (en) 1977-06-24
FR2334349B1 (en) 1983-07-22
NL7613660A (en) 1977-06-13
DE2655636A1 (en) 1977-06-23
DE2655636C2 (en) 1993-03-11
PT65934A (en) 1977-01-01
FR2334349A1 (en) 1977-07-08
GR63103B (en) 1979-09-05
NL177747B (en) 1985-06-17

Similar Documents

Publication Publication Date Title
DK148907C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF DIHYDROCYCLOSPORIN C
DK154289C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF N2-ARYLSULPHONYL-L-ARGININAMIDES OR SALTS THEREOF
DK499778A (en) PROCEDURE FOR THE PREPARATION OF 9- (OMEGAHETEROARYLAMINO-ALKYLAMINO) -ERYTHROMYCINES OR SALTS THEREOF
DK149107C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF QUINAZOLON DERIVATIVES
DK5976A (en) PROCEDURE FOR THE PREPARATION OF BIPHENYLOXIDE DERIVATIVES OR SALTS THEREOF
DK144525C (en) ANALOGY PROCEDURE FOR PREPARING 5-HALOGEN PYRIMID-2-ONES OR SALTS THEREOF
DK146205C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF 8ALFA ERGOLIN-I DERIVATIVES
DK27078A (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOQUINOLES OR SALTS THEREOF
DK209176A (en) PROCEDURE FOR THE PREPARATION OF N-SUBSTITUTED PHENYL PIPERIDE DERIVATIVES OR SALTS THEREOF
DK143902C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF 8ALFA ERGOLIN-I DERIVATIVES
DK139724C (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF PYRIDOBENZODIAZEPINONS OR SALTS THEREOF
DK324979A (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOQUINOXALINES OR SALTS THEREOF
DK511878A (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOBENZOAZEPINES OR SALTS THEREOF
DK385777A (en) PROCEDURE FOR THE PREPARATION OF CEPHALOSPORINE DERIVATIVES OR SALTS THEREOF
DK148139C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF 5-BENZYL-2-OXAZOLIDE UNDERTIVES
DK232777A (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOTHIAZINES OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
DK144301C (en) ANALOGY PROCEDURE FOR PENICILLIN OR SALT PREPARATION
DK223177A (en) PROCEDURE FOR THE PREPARATION OF P-ACYLAMINOBENZAMIDE COMPOUNDS OR SALTS THEREOF
DK127676A (en) PROCEDURE FOR THE PREPARATION OF 9-ALKYLAMINO-ERYTHROMYCINES OR SALTS THEREOF
DK338376A (en) PROCEDURE FOR THE PREPARATION OF AMINOBENZOCYCLOHEPTENDER DERIVATIVES OR ADDITIONAL SALTS THEREOF
DK147623C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF AZAPURIN DERIVATIVES OR SALTS THEREOF
DK146629C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF DEPOTTEROID EASTERS
DK232877A (en) PROCEDURE FOR THE PREPARATION OF 2-IMINO-3-AMINOTHIAZOLIDINES OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
DK146822C (en) ANALOGY PROCEDURE FOR PREPARING DERIVATIVES OF 4-DESACETYL-VINBLASTIN OR SALTS THEREOF
DK408176A (en) PROCEDURE FOR THE PREPARATION OF 5-THIAZOLMETHANAMINE DERIVATIVES OR SALTS THEREOF